Long-term efficacy and safety of infliximab maintenance therapy in patients with plaque-type psoriasis in real-world practice

British Journal of Dermatology

Volumn 171, Issue 3, 2014, Pages 631-641

  Shear, N H ^a   Hartmann, M ^b   Toledo Bahena, M ^c   Katsambas, A ^d   Connors, L ^e   Chang, Q ^e   Yao, R ^e   Nograles, K ^e   Popmihajlov, Z ^e  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c HOSPITAL INFANTIL DE MÉXICO FEDERICO GÓMEZ   (Mexico)

^d HYGEIA HOSPITAL   (Greece)

^e MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB; DERMATOLOGICAL AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTHRALGIA; ARTICLE; BASAL CELL CARCINOMA; BRONCHITIS; BRONCHOPNEUMONIA; CLOSTRIDIUM INFECTION; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ENTEROCOLITIS; FEMALE; GASTROENTERITIS; HEART ARREST; HEPATOBILIARY DISEASE; HERPES ZOSTER; HUMAN; HYPERSENSITIVITY; INFUSION RELATED REACTION; LEUKOPENIA; LONG TERM CARE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; OPEN STUDY; OUTCOME ASSESSMENT; PENIS CARCINOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; CLINICAL TRIAL; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; PSORIASIS; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; DERMATOLOGIC AGENTS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSORIASIS; TREATMENT OUTCOME;

EID: 84925304484     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.13004     Document Type: Article

References (12)

1. Ferrándiz C, Carrascosa JM, Boada A,. A new era in the management of psoriasis? The biologics: facts and controversies. Clin Dermatol 2010; 28: 81-7.
2. Menter A, Griffiths CEM,. Psoriasis 2: current and future management of psoriasis. Lancet 2007; 370: 272-84.
3. Menter A, Feldman SR, Weinstein GD, et al,. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2007; 56: e1-15.
4. Gottlieb AB, Evans R, Li S, et al,. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004; 51: 534-42.
5. Gottlieb AB, Matheson RT, Lowe N, et al,. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003; 139: 1627-32.
6. Lebwohl M, Christophers E, Langley R, et al,. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 2003; 139: 719-27.
7. Menter A, Gordon K, Carey W, et al,. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol 2005; 141: 31-8.
8. Reich K, Nestle FO, Papp K, et al,. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005; 366: 1367-74.
9. Patel V, Horn EJ, Lobosco SJ, et al,. Psoriasis treatment patterns: results of a cross-sectional survey of dermatologists. J Am Acad Dermatol 2008; 58: 964-9.
10. Barker J, Hoffmann M, Wozel G, et al,. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1). Br J Dermatol 2011; 165: 1109-17.
11. Edson-Heredia E, Sterling KL, Alatorre CI, et al,. Heterogeneity of response to biologic treatment: perspective for psoriasis. J Invest Dermatol 2014; 134: 18-23.
12. Kalb RE, Gurske J,. Infliximab for the treatment of psoriasis: clinical experience at the State University of New York at Buffalo. J Am Acad Dermatol 2005; 53: 616-22.